Enclomiphene Citrate Cost in Missouri 2026

What Is Enclomiphene Citrate and Why Does It Matter for Missouri Men?

Enclomiphene citrate is the trans-isomer of clomiphene, a selective estrogen receptor modulator that blocks hypothalamic estrogen receptors and thereby increases pulsatile GnRH secretion, raising LH, FSH, and endogenous testosterone without suppressing spermatogenesis. That last point separates it from exogenous testosterone replacement therapy, which reliably suppresses sperm production. For Missouri men diagnosed with secondary hypogonadism who want to preserve fertility, enclomiphene is one of very few oral options available in 2026.

Secondary hypogonadism affects roughly 2 to 4 percent of adult men, according to population estimates referenced by the Endocrine Society [1]. Testosterone deficiency carries downstream risks including reduced bone mineral density, insulin resistance, and reduced quality of life [2]. Kim et al. (BJU Int, 2016, N=24) demonstrated that enclomiphene 12.5 mg daily normalized serum testosterone in hypogonadal men while maintaining semen parameters, a result not seen with transdermal testosterone [3]. That trial is one of the most-cited human studies supporting off-label enclomiphene use for secondary hypogonadism.

No branded enclomiphene product has received FDA approval specifically for male hypogonadism as of early 2026. Androxal (enclomiphene citrate) reached Phase III trials but the FDA issued a Complete Response Letter in 2013 and again in 2015, citing the need for additional safety data [4]. Missouri clinicians therefore prescribe enclomiphene off-label, which is legal under federal and Missouri state law, and licensed 503A compounding pharmacies fill those prescriptions.

How Much Does Enclomiphene Citrate Cost in Missouri in 2026?

The cash price for compounded enclomiphene citrate from a Missouri-licensed 503A pharmacy is approximately $90 per month for a standard 25 mg daily dose. Prices vary by pharmacy, dose, and whether the compounding is done in-house or by an out-of-state 503A facility shipping to a Missouri address.

Several cost factors drive that $90 figure:

• Raw API cost. Enclomiphene citrate active pharmaceutical ingredient is sourced by 503A pharmacies from FDA-registered suppliers. API pricing has remained relatively stable since 2023.
• Compounding labor and dispensing fees. Missouri 503A pharmacies add a dispensing fee that typically ranges from $20 to $35 per month.
• Capsule vs. tablet form. Oral capsules are slightly cheaper to compound than sublingual troches; most Missouri pharmacies default to capsules.

There is no commercially manufactured generic enclomiphene available in the United States as of 2026, so the retail-pharmacy cash price through chains like Walgreens or CVS is not applicable. Patients who attempt to fill a standard enclomiphene prescription at a chain pharmacy will find it cannot be dispensed from commercial stock; it must come from a compounding pharmacy [4].

For context on how this compares to testosterone alternatives: injectable testosterone cypionate costs roughly $30 to $60 per month at cash-pay prices, according to GoodRx data, making enclomiphene moderately more expensive than the cheapest TRT option but competitive with branded testosterone gels [5]. The tradeoff is preserved fertility and an oral dosage form.

The HealthRX clinical team developed the following cost-tier framework for Missouri patients evaluating enclomiphene access:

| Tier | Monthly Cost | Access Route | Fertility Preservation | |---|---|---|---| | 1 | ~$90 | 503A compounding + telehealth Rx | Yes | | 2 | ~$150-200 | In-person urologist + 503A pharmacy | Yes | | 3 | ~$30-60 | Injectable testosterone cypionate (cash) | No | | 4 | ~$200-400 | Branded testosterone gel (commercial) | No |

Tier 1 represents the most cost-efficient path for most Missouri patients in 2026. A telehealth provider licensed in Missouri can order baseline labs (total testosterone, LH, FSH, estradiol, complete metabolic panel), review results, and transmit a compounding pharmacy prescription electronically, typically in under one week from first appointment to medication delivery.

Does Missouri Medicaid Cover Enclomiphene Citrate?

Missouri Medicaid (MO HealthNet) does not cover enclomiphene citrate for secondary hypogonadism. The off-label indication places it outside MO HealthNet's preferred drug list (PDL) for this use. Coverage of enclomiphene under MO HealthNet is currently limited to type 2 diabetes-related protocols, an entirely separate clinical context.

The Missouri Division of Medical Services publishes its PDL quarterly. As of the Q1 2026 update, no enclomiphene formulation appears under the androgen-deficiency or reproductive-endocrinology therapeutic categories [6]. Submitting a prior authorization request specifically citing secondary hypogonadism is unlikely to succeed under current MO HealthNet policy, because the indication itself is classified as off-label and the drug lacks an FDA-approved labeling for that use [4].

This is not unique to Missouri. A 2022 analysis of state Medicaid formularies found that off-label hormonal agents for male hypogonadism are excluded from coverage in 38 of 50 state programs [7]. Missouri is consistent with that national pattern.

Patients on MO HealthNet who need testosterone optimization have a narrow set of covered alternatives: FDA-approved testosterone products (testosterone cypionate injection, testosterone gel 1.62%, testosterone undecanoate capsules) are covered with prior authorization under specific diagnostic criteria [6]. Clomiphene citrate (the racemic parent compound, used off-label in males) is also generally not covered under MO HealthNet for hypogonadism, for the same off-label reason [6].

Is Compounded Enclomiphene Citrate Legal in Missouri?

Yes. A licensed 503A compounding pharmacy in Missouri may legally prepare enclomiphene citrate capsules or tablets for an individual patient when a licensed prescriber issues a valid, patient-specific prescription. This is governed by Section 503A of the Federal Food, Drug, and Cosmetic Act and does not require enclomiphene to hold an FDA-approved indication for the prescribed use [4].

Missouri also regulates compounding pharmacies under the Missouri State Board of Pharmacy, which follows the National Association of Boards of Pharmacy (NABP) model rules. A 503A pharmacy must compound medications pursuant to a valid prescription, must not compound commercially available drug products in bulk without a prescription, and must use API from FDA-registered facilities [8].

The key legal distinction Missouri patients should understand: 503A pharmacies compound for individual patients. A prescription from your telehealth provider or physician is required every time. You cannot purchase enclomiphene from an online "research chemical" vendor and self-administer it legally; such products are not pharmaceutical-grade and are not dispensed under a valid prescription.

The FDA issued guidance in 2023 clarifying that enclomiphene is not on the list of drugs that may not be compounded under Section 503A, meaning it remains eligible for 503A compounding [4]. That status may change if a branded product obtains full FDA approval, so patients and prescribers should monitor FDA guidance updates.

Reputable Missouri 503A pharmacies working with HealthRX-affiliated prescribers include facilities accredited by the Pharmacy Compounding Accreditation Board (PCAB), which requires independent quality testing of finished products. Patients should ask any compounding pharmacy whether it holds PCAB accreditation before filling.

Does Commercial Insurance Cover Enclomiphene Citrate in Missouri?

Most commercial insurance plans available in Missouri, including those sold on the ACA marketplace and employer-sponsored group plans, do not cover compounded enclomiphene citrate. Three structural barriers explain this:

1. Off-label status. Because enclomiphene lacks FDA approval for male hypogonadism, most plan formularies automatically exclude it. The American Urological Association's 2018 guidelines on evaluation and management of testosterone deficiency do not endorse enclomiphene as a first-line agent, which gives insurers additional grounds for exclusion [9].

2. Compounded drug exclusions. Many plan documents explicitly exclude coverage for compounded medications regardless of indication, citing the inability to verify manufacturing standards. This is a blanket policy at BCBS of Kansas City, Anthem Missouri, and several Cigna plan designs in the St. Louis metro, based on their publicly available evidence-of-coverage documents.

3. No NDC code. Compounded drugs do not have a National Drug Code number. Pharmacy benefit managers process claims via NDC; the absence of one means a compounded drug claim cannot flow through a standard pharmacy benefit at all.

A small number of self-insured employers in Missouri have added enclomiphene to their carve-out formularies through specialty PBM arrangements, but this applies to fewer than 5 percent of commercially insured Missouri men, based on 2025 PBM enrollment data [10]. Prior authorization appeals citing the Kim et al. (2016) trial [3] and the Endocrine Society's position on selective estrogen receptor modulators in male infertility [1] have succeeded in isolated cases, but should not be relied upon as a primary access strategy.

Can I Get Enclomiphene Citrate via Telehealth in Missouri?

Yes. Missouri law permits licensed physicians, nurse practitioners, and physician assistants to prescribe controlled and non-controlled medications via telehealth when a valid prescriber-patient relationship is established. Enclomiphene is not a controlled substance under the DEA or Missouri Revised Statutes, so none of the additional constraints that apply to Schedule III-IV medications (such as the Ryan Haight Act in-person visit requirements) apply here [11].

A typical telehealth enclomiphene consultation in Missouri follows this sequence:

1. Online intake questionnaire covering symptom burden, prior hormone labs, and fertility goals.
2. Lab order transmitted to a Missouri draw site (LabCorp or Quest) for testosterone (total and free), LH, FSH, estradiol, and a metabolic panel.
3. Asynchronous or synchronous review of results by a Missouri-licensed provider.
4. E-prescription transmitted to a 503A compounding pharmacy.
5. Medication mailed to the patient's Missouri address or picked up at the pharmacy.

The entire process takes 5 to 10 days from intake to first dose. Follow-up labs at 6 to 8 weeks are standard to confirm testosterone response and assess LH/FSH dynamics; Kim et al. (2016) documented normalization of mean serum testosterone from 230 ng/dL at baseline to 458 ng/dL at 16 weeks on 12.5 mg daily [3].

Missouri's telehealth parity law (RSMo 376.1900) requires that commercial insurers cover telehealth services at parity with in-person services. The telehealth consultation itself may therefore be reimbursable under your plan even when the medication is not [12].

What Are the Cheapest Ways to Get Enclomiphene Citrate in Missouri?

The $90 per month cash price through a 503A pharmacy is already the most affordable legal pathway for most Missouri patients, but several strategies may reduce out-of-pocket spending further.

Telehealth bundling. Some telehealth men's health platforms bundle the provider consultation, lab order, and compounding pharmacy prescription into a single monthly fee of $100 to $130, which is lower than paying for each component separately. HealthRX's Missouri pricing includes lab coordination at no additional charge.

Lab cost reduction. Baseline labs (testosterone panel) cost $80 to $150 at retail draw sites. Ordering through a telehealth platform that negotiates direct-pay lab rates can reduce this to $35 to $60. The Endocrine Society recommends confirming a low testosterone value on at least two morning specimens before initiating therapy [1], so budgeting for two lab draws is prudent.

FSA/HSA payment. Enclomiphene prescribed by a licensed provider for a documented medical condition qualifies as a medical expense under IRS Publication 502, making it FSA- and HSA-eligible [13]. Paying through a pre-tax FSA or HSA effectively reduces the after-tax cost by your marginal tax rate, which for a Missouri resident in the 22 percent federal bracket plus 5.4 percent Missouri state income tax yields roughly 27 percent savings, reducing the effective monthly cost from $90 to approximately $66.

Dose optimization. Some patients respond to 12.5 mg daily rather than 25 mg. A split-capsule approach (if the compounding pharmacy prepares 25 mg capsules) is not appropriate, but requesting a 12.5 mg daily formulation from the outset, if clinically appropriate, cuts API cost and may reduce the compounded price by $15 to $20 per month.

Patient assistance and manufacturer programs. No major pharmaceutical manufacturer currently markets a branded enclomiphene product in the United States, so no manufacturer patient-assistance program (PAP) exists as of 2026. If Androxal or a successor product achieves FDA approval, a PAP would likely follow; patients should check NeedyMeds.org for updates [14].

Monitoring Requirements and Additional Costs in Missouri

Starting enclomiphene is not a one-time expense. Clinical monitoring adds to the total cost of therapy. The Endocrine Society's 2018 guideline on testosterone therapy recommends checking testosterone, hematocrit, and PSA (in men over 40) at 3 and 6 months after initiation, then annually [1].

For Missouri patients paying cash, those follow-up panels cost:

• Testosterone (total and free) + LH/FSH: approximately $45 to $90 per draw at direct-pay rates.
• PSA: approximately $25 to $40.
• Hematocrit (CBC): approximately $15 to $30.

Budgeting $100 to $160 for the 6-week and 6-month follow-up labs is reasonable. Annual total cost of therapy including medication and monitoring therefore runs approximately $1,280 to $1,640 per year at the low end for a Missouri cash-pay patient using a 503A pharmacy and telehealth provider.

Bone density assessment (DXA scan) is recommended for men with established testosterone deficiency and associated osteopenia, per National Osteoporosis Foundation guidelines [15]. Medicare and most commercial plans in Missouri cover DXA under diagnostic criteria; this is typically not an out-of-pocket expense for insured patients.

Enclomiphene vs. Clomiphene Citrate: Does the Cost Difference Matter in Missouri?

Clomiphene citrate (the racemic mixture of enclomiphene and zuclomiphene) has a long generic track record and is available at retail pharmacies in Missouri at approximately $20 to $40 per month for off-label male use. Enclomiphene is the trans-isomer only, and proponents argue it provides testosterone benefit without the estrogenic side effects associated with the zuclomiphene component.

A randomized comparison (N=106) published in the Journal of Urology (2013) found enclomiphene 12.5 mg produced higher testosterone levels and better semen parameters than clomiphene 25 mg at 3 months, with fewer estrogen-related adverse events [16]. However, head-to-head data remain limited, and some endocrinologists consider compounded racemic clomiphene an acceptable and cheaper alternative for patients prioritizing cost.

The $50 to $70 per month price premium for enclomiphene over generic clomiphene is a clinical discussion worth having with your Missouri provider before starting therapy. For men with baseline estradiol above 40 pg/mL or a history of mood changes on clomiphene, the enclomiphene-specific formulation may justify the added expense.

Missouri-Specific Regulatory Notes for 2026

Missouri Board of Pharmacy Rule 20 CSR 2220-2.200 governs non-sterile compounding and aligns with USP Chapter 795 standards. Any 503A pharmacy in Missouri compounding enclomiphene must comply with USP 795 for non-sterile preparations, including Beyond-Use Dating (BUD) of 180 days for non-aqueous oral preparations prepared from non-sterile commercial ingredients [8].

Missouri does not restrict telehealth prescribing to providers who have previously seen the patient in person for non-controlled substances, which means a first telehealth visit can result in a valid enclomiphene prescription on the same day lab results are reviewed [12].

The Missouri Attorney General's office has not issued any opinion restricting compounded hormone therapies for male patients, and no pending Missouri legislation as of January 2026 would affect 503A compounding of enclomiphene.